Latest Ratios: P/E Ratio 0.0x · EV/EBITDA -0.5x · ROE 46.4%. (2007–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $437 | $38745 | $30240 | $309120 | $91356 | $322560 | $390960 | $471600 | $242820 | $259200 | $172800 |
| Enterprise Value | $-2392732 | $-2354424 | $23M | $24M | $30M | $25M | $39M | $17M | $4M | $-5413649 | $11M |
| P/E Ratio → | 0.00 | 0.00 | — | — | — | — | — | — | — | — | 0.36 |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| P/B Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.04 | 0.07 | 0.09 | 0.05 | 0.06 | 0.06 |
| P/FCF | 0.00 | 0.06 | — | — | — | — | — | — | — | 0.23 | 0.07 |
| P/OCF | 0.00 | 0.03 | — | — | — | — | — | — | — | 0.17 | 0.07 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.02 | 0.15 | 0.16 | 0.18 | 0.19 | 0.33 | 0.16 | 0.04 | -0.07 | 0.12 |
| EV / EBITDA | -0.48 | -0.47 | 12.49 | — | — | — | — | 21.37 | — | — | 7.77 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | 15.91 |
| EV / FCF | — | -3.72 | — | — | — | — | — | — | — | -4.71 | 4.76 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 3.2% | 3.2% | 20.1% | 23.0% | 22.2% | 22.0% | 21.8% | 23.3% | 20.9% | 20.4% | 19.7% |
| Operating Margin | -0.9% | -0.9% | -2.3% | -14.1% | -1.6% | -6.6% | -6.0% | -0.8% | -18.8% | -7.5% | -0.0% |
| Net Profit Margin | 8.5% | 8.5% | -2.7% | -14.2% | -1.9% | -6.1% | -5.0% | -0.9% | -17.7% | -6.9% | 0.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 46.4% | 46.4% | -27.4% | -107.3% | -13.5% | -37.6% | -32.5% | -5.2% | -74.9% | -24.6% | 2.4% |
| ROA | 12.8% | 12.8% | -4.6% | -21.4% | -3.0% | -7.9% | -6.8% | -1.3% | -24.2% | -8.7% | 0.7% |
| ROIC | -2.4% | -2.4% | -6.9% | -33.8% | -4.0% | -12.5% | -11.6% | -2.3% | -61.6% | -17.8% | -0.1% |
| ROCE | -4.1% | -4.1% | -15.7% | -74.2% | -7.3% | -21.2% | -23.5% | -4.8% | -78.1% | -25.9% | -0.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.35 | 0.35 | 3.02 | 2.53 | 2.14 | 1.92 | 2.90 | 1.53 | 1.02 | 0.48 | 0.91 |
| Debt / EBITDA | 2.09 | 2.09 | 23.36 | — | — | — | — | 32.43 | — | — | 12.32 |
| Net Debt / Equity | — | -0.08 | 1.61 | 1.40 | 1.33 | 1.01 | 2.04 | 0.98 | 0.21 | -0.21 | 0.57 |
| Net Debt / EBITDA | -0.48 | -0.48 | 12.47 | — | — | — | — | 20.78 | — | — | 7.65 |
| Debt / FCF | — | -3.78 | — | — | — | — | — | — | — | -4.94 | 4.69 |
| Interest Coverage | — | — | -305.63 | -314.00 | -7.00 | -17.33 | -8.22 | — | — | -4120.44 | 4.50 |
Net cash position: cash ($13M) exceeds total debt ($10M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.74 | 1.74 | 0.94 | 0.97 | 1.01 | 1.11 | 1.06 | 1.02 | 1.14 | 1.40 | 1.11 |
| Quick Ratio | 1.45 | 1.45 | 0.72 | 0.74 | 0.80 | 0.85 | 0.85 | 0.77 | 0.89 | 1.15 | 0.86 |
| Cash Ratio | 0.37 | 0.37 | 0.27 | 0.28 | 0.25 | 0.34 | 0.28 | 0.17 | 0.28 | 0.46 | 0.17 |
| Asset Turnover | — | 1.86 | 1.63 | 1.64 | 1.55 | 1.25 | 1.18 | 1.48 | 1.30 | 1.21 | 1.43 |
| Inventory Turnover | 11.90 | 11.90 | 7.60 | 7.48 | 7.98 | 6.12 | 7.50 | 5.91 | 5.66 | 6.54 | 6.62 |
| Days Sales Outstanding | — | 91.98 | 45.05 | 41.32 | 49.96 | 50.76 | 46.34 | 45.16 | 44.43 | 49.64 | 38.71 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 26285.7% | — | — | — | — | — | — | — | — | 281.3% |
| FCF Yield | 100.0% | 1632.5% | — | — | — | — | — | — | — | 443.0% | 1351.5% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $246 | $64 | $23 | $8 | $8 | $6 | $5 | $5 | $4 | $3 |
Regulatory-driven business model collapse
As reported in recent financial statements, Ridgetech's gross margin has compressed to a razor-thin 3.9% in 2026Q2, reflecting the company's limited pricing power as a price-taker in a market dominated by government-mandated volume-based procurement and intense regional competition for medical distribution contracts.
The persistent negative operating margins suggest that the company's fixed cost base remains misaligned with its shrinking revenue volume. Investors should monitor whether the company can achieve any meaningful scale, as the current cost structure appears to be structurally incompatible with the low-margin nature of pharmaceutical distribution.
Based on historical quarterly data, Ridgetech's ROIC has fluctuated wildly, reaching a low of -33.0% in 2023Q4, which underscores the company's inability to generate consistent returns on its invested capital amidst ongoing revenue contraction and the loss of key regional procurement tenders.
The erratic nature of these returns suggests that capital allocation has been reactive rather than strategic, likely driven by the need to cover operating deficits. The lack of a stable, positive ROIC trend warrants further investigation into whether the company possesses any remaining competitive advantage in its core markets.
According to recent quarterly filings, Ridgetech's asset turnover has remained stagnant at approximately 1.00, indicating that the company is struggling to optimize its inventory and receivables in a high-volume, low-margin environment that is increasingly sensitive to regulatory-driven payment delays from hospital clients.
The volatility in the cash conversion cycle, which has fluctuated significantly over the last ten quarters, suggests that management is facing persistent challenges in managing supplier and customer leverage. This inefficiency likely exacerbates the company's liquidity constraints, making it difficult to maintain the necessary inventory levels for competitive bidding.
As indicated by the latest balance sheet data, Ridgetech has aggressively reduced its debt-to-equity ratio from 2.14 in 2022Q2 to 0.16 in 2026Q2, a shift that appears to be a forced response to shrinking operational scale rather than a strategic decision to optimize the capital structure.
While the low debt levels might appear to provide a buffer, the lack of access to credit may actually hinder the company's ability to scale or participate in larger, more capital-intensive procurement tenders. Investors should monitor whether this deleveraging is a sign of financial discipline or a symptom of a shrinking business that can no longer support traditional debt financing.
The market may be misinterpreting Ridgetech's occasional positive net margins as a sign of a successful turnaround, while the negative operating margin suggests the core business remains in decline, obscuring the reality that reported profits are likely derived from non-core, non-recurring sources.
Analysts should prioritize operating cash flow and operating margins over net income to assess the true health of the distribution business. Relying on net income in this context is a common error that masks the underlying operational deficits and the potential for long-term value destruction.
Includes 30+ ratios · 18 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RDGT stock.
Ridgetech Inc.'s current P/E ratio is 0.0x. The historical average is 0.2x.
Ridgetech Inc.'s current EV/EBITDA is -0.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 7.4x.
Ridgetech Inc.'s return on equity (ROE) is 46.4%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -23.6%.
Based on historical data, Ridgetech Inc. is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.
Ridgetech Inc. has 3.2% gross margin and -0.9% operating margin.
Ridgetech Inc.'s Debt/EBITDA ratio is 2.1x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.